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Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein
metabolism. The nephrotic syndrome is characterized by proteinuria,
hypoalbuminemia, and hypercholesterolemia. Hypertriglyceridemia of-
ten is present as well. In this study, the kinetics of plasma lipoproteins
were investigated in four patients with nephrotic hyperlipidemia, and
repeat studies were carried out in three of these patients during therapy
with lovastatin. Before lovastatin therapy, the patients had an ex-
tremely delayed catabolism of very low density lipoproteins (VLDL)
without evidence of overproduction of lipoproteins in this fraction.
Three of four patients had elevated levels of low density lipoprotein
(LDL) that were due mainly to increased production rates for LDL. In
the three patients treated with lovastatin, the drug therapy lowered
plasmaconcentrations oftotalcholesterol, triglycerides, VLDL-choleste-
rot, and LDL-cholesterol, and raised high density lipoprotein (HDL)-
cholesterol. Lovastatin therapy decreased VLDL-triglycerides prinlar-
ily by enhancing their catabolism, and lowered LDL-cholesterol levels
mainly by reducing input rates for LDL. Overall, lovastatin appears to
be an effective drug for the treatment of hyperlipidemia in the nephrotic
syndrome.
The nephrotic syndrome is a renal disorder of diverse etiol-
ogy typified by proteinuria, hypoalbuminemia, and sometimes
edema. Hypercholesterolemia usually is present in nephrotic
patients and is considered by some to be an essential compo-
nent [1, 2]. As the disorder progresses, hypertriglyceridemia, or
combined hyperlipidemia, can develop [31. Many cases of
nephrotic syndrome in adults are secondary to diabetes mclii-
tus, while primary forms of nephrotic syndrome most often are
due to membranous nephropathy, focal sclerosis, and minimal
change disease [4], Prolonged hyperlipidemia associated with
the nephrotic syndrome apparently can produce accelerated
atherosclerosis and premature coronary heart disease (CHD)
[5, 61, Hyperlipidemia of the nephrotic syndrome is typically
resistant to therapy. Resolution of the hypoalbuminemia often
but not invariably restores plasma lipids to normal [2, 7, 8], but
as long as significant proteinuria remains, hyperlipidemia usu-
ally persists.
Since nephrotic hyperlipidemia seemingly predisposes to
CHD, some means to reduce plasma lipid levels in nephrotics
seems desirable. The recent introduction of drugs that curtail
cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl
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coenzyme A (HMG Co A) reductase offers a new promise for
treatment of severe hypercholesterolemia [9]. Lovastatin is one
agent in this category [10—13], and this drug could reduce
plasma cholesterol, and possibly triglycerides, in patients with
nephrotic hyperlipidemia. In the current study, we have exam-
ined three questions: (a) what are the defects in lipoprotein
kinetics responsible for nephrotic hyperlipidemia? (b) does
lovastatin significantly reduce plasma concentrations of choles-
terol and triglycerides in patients with the nephrotic syndrome?
and (c) if so, by what mechanisms do these changes occur?
Methods
Patients
Four patients with the nephrotic syndrome and hyperlipid-
emia were admitted to the metabolic ward of the Veterans
Administration Medical Center, Dallas, Texas. The character-
istics of these patients are presented in Table I. They had
proteinuria ranging from 6.5 to 14.5 g/day and clinically signif-
icant hypoalbuminemia; however, they did not have marked
elevations of plasma creatinine, nor severe nephrotic syn-
drome. Three patients had the apolipoprotein (apo) E31E3
phenotype and one had apo E3/E4. None had an increase in
very low density lipoprotein (VLDL)-cholesterol!plasma total
triglyceride ratio. Three of the patients (Nos. 1, 3, and 4) had
previously undergone renal biopsy that revealed membranous
glomerulonephritis; in the fourth patient (No. 2), a tissue
diagnosis was not available. None of the patients had clinically-
manifest atherosclerotic disease at time of study, but one
patient (No. I) died suddenly, possibly of myocardial infarc-
tion, several months after the study. None of the patients were
on steroid or diuretic therapy, and they were not edematous.
All patients were euthyroid. Each gave informed consent for
the research protocol that was approved by the appropriate
institutional review board.
Experimental design
Three patients (Nos. I to 3) underwent studies on the
metabolic ward during two periods. Patient 4 underwent only
the first period. Each period lasted a minimum of eight weeks.
The first period was for control, during which time patients did
not receive any hypolipidemic drugs. During the second period,
patients received lovastatin, 20 mg twice daily. Patients were
started on a metabolic diet on the fifth week of each period; they
had a one-unit plasmapheresis during the sixth week, and on the
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Table 1. Clinical data
VLDL-cholesterol for this table was measured on VLDL isolated at d > 1.006 gIml.
first day of the seventh week they received intravenous injec-
tions of autologous '251-VLDL and '311-LDL. The lipoprotein
turnover studies were conducted for 14 days.
Diets
Two weeks before and throughout the lipoprotein turnover
study in each period, the patients ate a solid food diet contain-
ing 40% of calories as fat (17% saturates, 18% monounsatur-
ates, and 5% polyunsaturates), 45% as carbohydrates, and 15%
as protein; intakes of cholesterol were approximately 300
mg/day [14]. The patients were maintained at constant weight
throughout the study.
Plasma lipids and lipoproteins
Plasma total cholesterol and triglycerides were measured
enzymatically [15, 16]. Chylomicrons were removed by ultra-
centrifugation before lipoprotein analyses were performed (17].
VLDL-cholesterol was measured on the fraction of lipoproteins
isolated at d < 1.019 g/ml by preparative ultracentrifugation [17,
18], and [LDL + HDL]-cholesterol was determined in the
infranatant. HDL-cholesterol was measured after precipitation
of LDL from the infranatant with heparin-manganese, and
LDL-cholesterol was calculated by the difference. Isoforms of
apo E were determined on VLDL by isoelectric focusing;
focusing was carried out on two samples of VLDL-protein, one
incubated with 13-mercaptoethylamine and another with 2-/3-
mercaptoethanol (191.
Kinetics of apo B—containing lipoproteins
The kinetic parameters for apo B were estimated in VLDL (d
< 1.019 g/ml) and in LDL (d l.0l9 to 1.063 g/ml). The details of
these measurements and justification for including all lipopro-
teins of d < 1.019 g/ml in the VLDL fraction were presented
recently [20]. The procedures employed in the turnover study
will be described briefly. Each patient began the metabolic diet
ten days before plasmapheresis and remained on the diet
throughout the turnover study. Five days before starting the
turnover study, 200 ml of plasma were obtained by plasmapher-
esis, and patients were started on supersaturated potassium
iodide (0.5 g/day) to inhibit thyroidal uptake of radioactive
iodine. VLDL and LDL were isolated from plasma by prepar-
ative ultracentrifugation; VLDL was labeled with 125jand LDL
was labeled with 311, both with the iodine-monochloride tech-
nique, as described previously (20]. Both isotopically-labeled
lipoproteins were injected intravenously at the same time. For
the first two days of the turnover study, the day's total caloric
intake was divided into six meals of identical calories consumed
every four hours. The composition of these meals was identical
to that consumed over the whole study.
Blood samples were collected 18 times in the first 48 hours
and then daily for the remaining 14 days. The details of the
procedure for isolation of lipoprotein fractions and determina-
tion of radioactivity and mass of apo B in each fraction have
been described before (20]. Briefly, VLDL and LDL were
isolated by preparative ultracentrifugation, and radioactivity in
apo B in VLDL and LDL was determined in each of the 18
samples collected during the first 48 hours. The technique for
determination of radioactivity in apo B of each fraction has
been outlined previously [20]; the procedure employed isopro-
panol for the precipitation of apo B to separate it from soluble
apoproteins. A single pool was made of all samples obtained
over the first 48 hours for determination of plasma VLDL-apo B
concentration for the purpose of estimating the plasma pool size
of VLDL-apo B.
Radioactivity in LDL was monitored in 30 samples obtained
during the entire period of study. Aliquots of fasting plasma
samples in the last 12 days of the study were combined into four
3-day pools for determinations of plasma lipids, lipoprotein-
cholesterol, and LDL-apo B concentrations. A single pool of all
samples was made for estimation of concentration and pool size
of LDL-apo B. Radioactive decay curves for VLDL-apo B and
LDL-apo B were constructed, and kinetic parameters were
determined by multicompartmental analysis.
Simulation analysis was employed to estimate kinetic param-
eters of apo B in VLDL and LDL. A multicompartmental
model, modified from Beltz et al [21] and reported recently [201
was employed in the analysis of the data. Figure I is a
schematic representation of this model, which is our hypothesis
of apo B metabolism in plasma. Although this model obviously
is an oversimplication of apo B metabolism as a whole, it
nonetheless appears to represent the major components of apo
B metabolism. Typical isotopic decay curves for VLDL-apo B
and LDL-apo B for a normal subject are presented in Figure 2.
The multicompartmental model shown in Figure 1 is designed to
account for the various components of these curves. It consists
of three subsystems: one describes the kinetics of LDL-apo B.
another VLDL-apo B, and a third, nascent lipoproteins.
The LDL subsystem consists of two pools of LDL [22]. one
representing the intravascular pool (L) and the other, the
extravascular pool (Li). This simple two-pool model is used to
explain the biexponential decay curve of radiolabeled LDL-apo
B in plasma (Fig. 2). The model assumes that all LDL is
removed irreversibly from plasma, and that all LDL in the
extravascular space must return to plasma for degradation. The
model further assumes that LDL in the intravascular space is
Age
Body
mass
index Apo E
Plasma
creatinine
Urinary
protein
Serum
albumin
VLDL-
cholesterol
triglycerides
Patient yrs kg/rn2 phenotype mg/c/I gldcmy gidi ratio
I 64 24.5 E3/3 2.5 6.5 2.7 0.25
2 69 23.7 E3/3 1.7 10.2 2.6 0.20
3 47 28.9 E3!3 1.0 14.5 2.5 0.28
4 69 24.5 E4/3 1.0 12.0 2.0 0.22
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kinetically homogenous, Although there is evidence that LDL
is not always completely homogenous in its kinetic behavior,
we have previously shown that the two-pool model provides a
close approximation of LDL-apo B kinetics under most circum-
stances [231. Plasma LDL can originate from the VLDL sub-
system, or it can enter the LDL compartment independent of
plasma VLDL, Although some investigators contend that LDL
can be secreted directly by the liver [241, we have assumed that
it is derived mainly from a compartment of nascent lipoproteins
(N) that has a very fast turnover rate; evidence to support this
concept has been presented before [21, 25, 261. In our analysis,
the kinetic parameters for 1251-LDL-apo B and 1311-LDL-apo B
were assumed to be equal.
The typical shape of the decay curve for radiolabeled VLDL-
apo B in plasma also is shown in Figure 2. The graph describes
the fraction of injected dose of VLDL-apo B remaining in
plasma at various time intervals during a two day period
following injection of radiolabeled VLDL. This curve has three
components: (a) a "shoulder" at the beginning of the curve
when decay is relatively slow, (b) a longer phase of rapid decay,
and (c) a "tail" of slow decay. The shoulder and the phase of
rapid decay are represented in the model by the chain pathway
(Via —*I). This chain pathway is similar in principle to the
delipidation cascade reported for VLDL-triglycerides [271. Li-
poproteins are assumed to enter into the first compartment of
the chain from nascent lipoproteins (compartment N). The
number of compartments in the chain can vary depending on
the length of the shoulder of the curve. In our model, interme-
diate density lipoproteins (IDL) represent the last pool in the
chain pathway; results obtained in our previous collaborative
studies [21, 25, 261 justify this concept. In other words, IDL is
assumed to be the terminal product of VLDL delipidation,
whereas delipidation of IDL results in formation of LDL.
VLDL-apo B in the chain pathway can have three fates: (a)
direct removal from the circulation as IDL-apo B, (b) conver-
sion to LDL, and (c) conversion to slowly catabolized VLDL
(V2).
Fig. 1. Multicompartmental model for kinetics of
apolipoprotein B. Compartment N represents
short-lived nascent lipoproteins and is a hypothetical
pool that cannot be identified by current techniques.
The VLDL subsystem contains two components.
The chain pathway for delipidation of VLDL is
represented by the Via —a—+--a V, —a I. The slow
pathway for VLDL is compartment V2; it may arise
either as a side product of the chain pathway or
from compartment N. The LDL system is
represented by a two-pool model containing an
intravascular compartment (Lp) and an extravascular
pool (Lx). This figure shows the interconnections
between the compartments.Out out
A
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Fig. 2. Typical decay curves for (A) VLDL-apo B and (B) LDL-apo B.
The VLDL-apo B contains three components. The "shoulder" at the
beginning of the curve and the phase of rapid decay account for the
chain pathway (Via V10 —a 1) and the tail of the curve indicates
the need for a slow pathway (Fig. I). The decay of LDL-apo B is
biexponential, and can be explained by a two-pool model of the LDL
subsystem.
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Table 2. Plasma lipids and lipoproteins
Total Total
Patient cholesterol triglyceride VLDL
Lipoprotein-cholesterol
LDL HDL
mg/dI SD"
No. I
Control 381 10 314 12 102 11 249 14 30 2
Lovastatin 261 2lL 183 9" 60 6" 167 8" 34 3"
No, 2
Control 286 9 297 33 80 7 168 2 37 4
Lovastatin 194 4b 221 58 4" 89 8" 48 2"
No. 3
Control 546 27 652 228 243 12 292 25 12 2
Lovastatin 378 28b 349 115 15" 239 75b 23 2"
No.4
Control 282 32 516 101 148 9 125 10 19 2
Mean SD for four 3-day pools of fasting plasma for days 2 to 14 of the turnover study.h Significantly different from control by Student's 1-test (P < 0.05).
Table 3. Kinetics of VLDL-apo B
VLDL-apo B
The plasma VLDL subsystem contains another compartment
(V2), which is a slowly catabolized pool. Its presence is
revealed by the tail on the VLDL-apo B decay curve (Fig. 2).
Compartment V2 can arise either "directly" from nascent
lipoproteins (compartment N) or as a side product of the chain
pathway (VI_—s—I). Any slowly catabolized IDL is assumed
to reside in the V., compartment. Apo B in compartment V2 can
be removed directly from the intravascular pool or be converted
to LDL.
The final subsystem of the model consists of hypothetical
nascent lipoproteins (compartment N). All apo B-containing
lipoproteins are assumed to enter plasma as nascent particles
[281. This compartment cannot be identified in plasma because
of its very high turnover rate. Its presence in the system has
been deduced from several lines of evidence considered previ-
ously [211. This compartment will henceforth be referred to as
the very fast pathway. Apo B in compartment N theoretically
can have three fates: (a) rapid direct removal from the circula-
tion, (b) rapid direct conversion to LDL, and (c) passage into
the chain pathway and/or slow pathway for VLDL catabolism.
En the discussion to follow, the term 'transit time" is defined
as the average time in which apo B entering a compartment
remains in the compartment [29]. The transit time for apo B is
equivalent to the reciprocal of the fractional catabolic rate
(FCR), which is defined as the fraction of total apo B in a
compartment that is removed in a given period of time. The
transport rate (or production rate) is defined as the rate at which
a species enters (and irreversibly leaves) a compartment. The
term "direct removal" for VLDL-apo B refers to the fraction of
the transport rate for VLDL-apo B that leaves the circulation
before conversion to LDL [21]. The "direct input" for LDL-
apo B is the fraction of apo B transported in LDL that is not
derived directly from the chain or slow pathways for VLDL-
apo B; as indicated above, the "direct" input of LDL is
assumed to be derived from compartment N.
Statistical analysis
Linear statistical packages available in CLINFO were used.
Comparison of means was carried out by paired t-test. Analysis
of kinetic data was carried out using the Simulation Analysis
and Modeling (SAAM) program of Berman and Weiss [301 in its
conversational mode (CONSAM) [31], using a VAX 11/780 or
VAX 11/750 computer.
Patient
Concentration Pool size
Transit
time
Transport
rate
Direct
removal
mg/dl SD mg days mg/kg-day %
No. 1
Control
Lovastatin
No. 2
Control
Lovastatin
No. 3
Control
Lovastatin
No. 4
Control
Normal men (N = 5)
(mean 5EM)
[Ref. 211
23 725 0.55 18.5 58
26 1304 1.87 8.8 40
14 706 1.14 7.8 38
60 2215 1.30 18.4 56
21 814 0.47 16.9 53
26 804 1.18 6.0 41
14.5 1.0 522 36 0.43 0.06 12.5 2.2 29 1.6
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Table 4. LDL-apo B kinetics
FIg. 3. Isotope kinetic curves for VLDL-apo B for
four patients with nephrotic syndrome during the
control period (•, patients 1—4) and during
lovastatin therapy (A, patients 1—3). In the control
period, all of the curves demonstrated a prolonged
convexity ("shoulder") without an identifiable slow
component (compartment V2). In patients 1—3,
lovastatin therapy accelerated the rate of decay, and
in patients 1 and 3, but not in patient 2, the
prolonged convexity of the curve was eliminated.
Patient
LDL-apo B
Conc
ing/di so
Pool size
mg
FCR
pools/day
Transport
rate
mg/kg-day
Direct
input
%
No. I
Control
Lovastatin
No. 2
Control
Lovastatin
No. 3
Control
Lovastafin
No.4
Control
171
117
125
72
228
158
104
5455
3897
4461
3420
8591
6307
3469
0.28
0.26
0.20
0.24
0.29
0.28
0.34
21.2
14.3
11.5
5.2
25.6
18.2
16.1
90
54
54
6
41
43
78
Results
Plasma lipids and lipoproteins
In the control period, all four nephrotic patients had mild-to-
moderate elevations of both plasma total cholesterol and tri-
glycerides (Table 2). In each patient, VLDL-cholesterol levels
were increased markedly. LDL-cholesterol concentrations were
strikingly elevated in two patients (Nos. 1 and 3), was mildly
increased in one (No. 2), and was not increased in the fourth
(No. 4). HDL-cholesterol levels were uniformly reduced. Three
of the patients underwent lovastatin therapy, and in them,
lovastatin lowered plasma concentrations of total cholesterol,
triglycerides, VLDL-cholesterol and LDL-cholesterol, and raised
HDL-cholesterol. In patient 3, plasma lipid levels were severely
elevated before therapy, and despite a marked reduction in lipid
concentrations during treatment with lovastatin, this patient
remained hyperlipidemic on drug therapy.
Metabolism of VLDL-apo B
The metabolic parameters of VLDL-apo B are presented in
Table 3, and isotope kinetic curves for this fraction are given for
control and lovastatin periods in Figure 3. In the control period,
the decay curves for all the four patients had a unique shape. In
Figure 4, decay curves for three normal, middle-aged men, who
were reported previously [25], are shown for comparison. In the
nephrotic patients, rates of disappearance of radioactivity in
VLDL-apo B were very slow and had a prolonged "shoulder"
without a definite "tail". This unusual shape suggests that the
defect in triglyceride metabolism in the nephrotic patients
resided in the chain pathway which contributes to
the shoulder of the curve, and not in the slow pathway (V2),
which is responsible for the tail. Since a slow pathway (V2)
could not be identified for these patients, the turnover of the
whole VLDL-apo B fraction was equated with the chain path-
way (Table 3). For all four patients, concentrations of VLDL-
apo B were abnormally high compared to levels in normal,
middle-aged men [25]. These high levels in nephrotic patients
were attributed to a prolonged transit time of apo B in the
VLDL chain pathway. Transport rates in the chain pathway
were not abnormally high, except in patient 3, who was obese.
Percent direct removal of VLDL-apo B varied considerably
among the patients.
Treatment of three patients with lovastatin induced a signif-
icant fall in concentrations of VLDL-apo B (Table 3). This
1 .0
.'... Control
0.1 Lovastatin00
C,
V .5?.
m ooca.
0.0 0.4 0.8 1.2 1.6 2.0
1.0
0.1
21.0
---_•—-- Control
0.1 Lovastatin
0.0 0.4 0.8 1.2 1.6 2.0
41.0
.
0.1
3
•
' •—.-.. Control
0.0 0.4 0.8 1.2 1.6 2.0 0.0 0.4 0.8 1.2 1.6 2.0
Time, days
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0.0 0.4 0.8 1.2 1.6 2.0
Fig. 4. Isotope-kinetic curves for VLDL-apo B for three normal, mid-
dle-aged men reported previously 19]. These curves were constructed
from isotope kinetic curves of VLDL-apo B and IDL-apo B by
computer summation. Each patient received an intravenous injection of
radioiodinated VLDL. These curves typically have three components—
an early "shoulder', a phase of rapid linear decay, and a slow
component ("tail").
reduction was accompanied by an alteration in the shape of
decay curve in two patients (Nos. I and 3) but not in a third
(No. 2; Fig. 3). In the former two patients, the prolonged
convexity of the curve was eliminated, and a more normal
configuration was restored. Compared to the control period,
treatment with lovastatin produced a decrease in the residence
time of apo B in the VLDL chain pathway. However, the
decreased residence time was not associated with a detectable
increase in the percentage of direct removal of VLDL-apo B
In two patients (Nos. 2 and 3), the rate of transport in the
VLDL chain pathway was not altered by lovastatin therapy, but
for unexplained reasons, the transport rate actually was in-
creased in patient I.
Metabolism of LDL-apo B
In the control period, concentrations of LDL-apo B ranged
from 104 to 228 mg/dl (mean = 157 27 (SE) mg/dl; Table 4).
FCRs for LDL-apo B varied between 0.20 and 0.34 pools/day
(mean = 0.28 0.03 pools/day), and transport (input) rates for
LDL-apo B varied between 11.5 and 25.6 mg/kg-day (mean =
18.6 3.1 mg/kg-day). The fraction of "direct input" for
LDL-apo B (N L) ranged from 41 to 90%. Lovastatin therapy
uniformly lowered plasma concentrations of LDL-apo B. The
major effect of lovastatin on LDL kinetics was to decrease the
transport rate for LDL-apo B; in addition, in two of the three
patients, lovastatin caused a marked reduction in the "direct
input" of LDL-apo B (N — L). Despite the fall in LDL-apo B
concentration, FCRs for LDL-apo B were not consistently
increased.
Discussion
Mechanisms for elevated LDL-cholesterol
Increased plasma concentrations of LDL-cholesterol in the
nephrotic syndrome could be due to overproduction of lipopro-
teins by the liver or to defective clearance of LDL. Isotope
kinetic studies alone cannot differentiate between these two
mechanisms with certainty, although they can provide strong
support for one or the other. For example, we have previously
shown that most patients with primary moderate hypercholes-
terolemia have low FCRs for LDL-apo B, suggestive of a
deficiency of LDL receptors [40]. Patients with homozygous or
severe heterozygous familial hypercholesterolemia (FH) like-
wise have marked reductions in FCRs for LDL, but they can
have an increased input of LDL as well [41]; in FH patients, the
enhanced input of apo B into the LDL compartment appears to
be secondary to a decreased clearance of VLDL remnants, the
precursors of LDL [42]. Since VLDL remnants, like LDL, are
removed by LDL receptors, the marked reduction of LDL
receptor activity in FH patients retards uptake of VLDL
remnants resulting in a greater conversion of VLDL to LDL.
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The mechanisms for hyperlipidemia in thc ephrotic syn-
drome have not been studied extensively in humans, but
elevated plasma lipids probably are due in part to overproduc-
tion of lipoproteins by the liver [32—34]. Hypoalbuminemia and
the resulting decreased plasma oncotic pressure have been
reported to stimulate the synthesis of both lipids and lipopro-
teins in livers of experimental animals [35, 36]. A similar
phenomenon has been noted in cultured hepatocytes [37, 38].
This overproduction could account for increases in plasma
levels of both VLDL and LDL found in many patients with the
nephrotic syndrome. When hypoalbuminemia becomes severe,
however, lipolysis of plasma triglycerides also may be inhibited
and thereby accentuate the hypertriglyceridemia [39]. In the
current study, we examined the metabolism of VLDL-apo B
and of LDL-apo B in four nephrotic patients in the attempt to
define the mechanisms responsible for their diverse forms of
hyperlipidemia; in addition, three of these patients were then
given lovastatin to determine the actions of this drug on
lipoprotein metabolism. The factors responsible for nephrotic
Time, days hyperlipidemia can be considered first.
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Table 5. Comparison of LDL kinetics in nephrotic patients to other categories of hypercholesterolcmia
Values are presented as means SEM.
However, our previous studies [40] in hypercholesterolemic
patients suggest that, regardless of input rates for LDL, a
decrease in FCR for LDL is almost always present in patients
with reduced activity of LDL receptors.
Parameters of LDL metabolism in our four nephrotic patients
can be compared to those of other groups studied previously in
our laboratory: normal middle-aged men, men with primary
moderate hypercholesterolemia, and patients with heterozy-
gous familial hypercholesterolemia (Table 5). The comparison
is presented to provide perspective, but the data cannot be
strictly compared statistically. On the whole, the nephrotic
patients had increased plasma concentrations of both LDL-
cholesterol and LDL-apo B. However, compared to patients
with primary (or familial) forms of hypercholesterolemia, the
FCRs for LDL-apo B in the nephrotic patients were not
similarly reduced; instead, elevated LDL concentrations in the
nephrotic patients appeared to be due mainly to increased
transport (production) rates for LDL. The absence of reduced
FCRs for LDL supports the concept that overproduction of
precursor lipoproteins is the major cause of the increased LDL
level in nephrotic patients. As shown in Table 4, a high fraction
of the increased input of LDL was via a "direct pathway", that
is, by direct conversion of nascent lipoproteins to LDL; in a
word, LDL was not derived exclusively from VLDL-apo B
passing through the chain pathway.
Despite evidence for overproduction of precursors of LDL,
we have not ruled out the possibility that a reduced activity of
LDL receptors was present as well. For example, patient 2 had
a very low FCR for LDL and a relatively normal input rate for
LDL, suggestive of reduced receptor activity. Many years ago,
Gitlin et al [43] reported that hypercholesterolemic patients with
the nephrotic syndrome have defective clearance of plasma LDL,
and one mechanism for a sluggish clearance of LDL could be a
reduced activity of LDL receptors. For example, hepatic syn-
thesis of LDL receptors could be curtailed by an increased
production of cholesterol in the liver. Studies in laboratory
animals with nephrosis suggest that hepatic cholesterol synthe-
sis is increased [35, 36], and if so, the accumulation of choles-
terol in the liver could suppress the activity of genes encoding
for LDL receptors and thereby reduce the synthesis of LDL
receptors [44]. Thus, the hypercholesterolemia of the nephrotic
syndrome could be multifactorial, although our isotope kinetic
data suggest that overproduction of precursors of LDL was the
major reason for increased LDL-cholesterol concentrations in
most of our patients.
Mechanism for hypertriglyceridemia
While overproduction of hepatic lipoproteins likely caused
the elevated levels of LDL-cholesterol in our nephrotic pa-
tients, the data for VLDL kinetics demonstrated that defective
clearance of triglyceride-rich lipoproteins was the major reason
for the hypertriglyceridemia. The shape of the isotopic decay
curves for VLDL-apo B strongly implied that the patients had a
slow delipidation of VLDL in the chain pathway. Previously, a
convexity, or "shoulder", at the beginning of the decay curve
has been attributed to a stepwise transport of lipoproteins
through the VLDL delipidation chain [21, 27, 45]. In the present
study, this convexity persisted throughout the whole of the two
days, suggesting a marked reduction in the rate of delipidation
of VLDL. Indeed, considering the sluggish rate of delipidation,
it is surprising that the hypertriglyceridemia was not more
severe, especially if the patients had a concomitant overpro-
duction of VLDL particles by the liver. However, transport
rates for VLDL-apo B were not increased, which suggests that
most of the excessive input of lipoproteins was shunted directly
into LDL (N —* L) without passing through the delipidation
chain for VLDL. Our data therefore imply that the hypertri-
glyceridemia of the nephrotic syndrome is not due primarily to
overproduction of VLDL, but rather to delayed lipolysis of
VLDL-triglycerides.
How can the delayed lipolysis of VLDL-triglycerides in our
patients be explained. Several possibilities can be considered.
First, urinary loss might deplete VLDL of apo C-Il which is
required for activation of lipoprotein lipase [46]. In nephrotic
animals, however, abundant apo C-Il is available in plasma for
activation of lipoprotein lipase 146—48], and this mechanism for
hyperlipidernia seems unlikely. Second, the activity of lipopro-
tein lipase or hepatic triglyceride lipase could be reduced or
inhibited by other mechanisms [49—51]. Finally, a delay in
clearance of triglyceride-rich lipoproteins could have been due
in part to a reduced activity of LDL receptors, because LDL
receptors are known to remove VLDL remnants from the
circulation [42]. Certainly, hypertriglyceridemia is not a char-
acteristic of patients with a primary deficiency of LDL recep-
tors, such as in familial hypercholesterolemia, and it is doubtful
that a reduced LDL receptor activity could account fully for the
elevations of triglyceride-rich lipoproteins noted in our patients.
Still, a decrease in number of LDL receptors could have
combined with an abnormality in the lipolytic system to reduce
the rate of catabolism of these lipoproteins.
Group
'.lephrotic syndrome
ormal middle-aged men
rimary-moderate
hypercholesterolemia
amilial
hypercholesterolemia
LDL-apo B
Ref.
No. of
patients
LDL-chol
Cone
mgldl
Cone
mgldl
FCR
pools/day
Transport
mg/kg-day
18.6 3.1— 4 208 38 157 27 0.28 0.03
56 14 144 6 101 5 0.30 0.01 13.5 0.7
40 12 199 7 129 + 3 0.24 0.01 12.9 0.7
57 281 3 168 9 0.22-v 0.04 16.5 1.3
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.Eftects of lovastatin
In the three patients treated with lovastatin, the drug caused
a marked reduction in concentrations of total cholesterol and
LDL-cholesterol. It further lowered levels of total triglycerides
and VLDL-cholesterol. Finally, it caused a significant increase
in HDL-cholesterol concentrations in all three patients. Thus,
while we treated only three patients with lovastatin, the results
were highly consistent for all three, and investigation of a larger
number of patients likely would not have provided additional
information about mechanisms for these changes. The effects of
lovastatin therapy on lipoprotein kinetics can be considered
briefly.
Mechanisms for LDL lowering. The major action of lovasta-
tin on the metabolism of LDL was to decrease the transport rate
of LDL-apo B. Drug therapy did not cause an increase in FCR
for LDL. This finding raises the possibility that the primary
mechanism for lowering of LDL levels by lovastatin was to
curtail the synthesis of lipoproteins by the liver. While we
cannot exclude this possibility, previously available evidence
indicates that a major action of lovastatin is to increase the
activity of LDL receptors [52—54]. If so, a decreased input of
apo B into the LDL compartment could be explained by
enhanced receptor-mediated clearance of precursors of LDL,
particularly nascent lipoproteins in compartment N. Previ-
ously, we reported that lovastatin caused a reduced input of
LDL in patients with primary moderate hypercholesterolemia,
and it had little effect on FCRs of LDL in these patients [40]. On
the other hand, we have found that lovastatin does not lower
plasma concentrations or transport rates for LDL in patients
with receptor-negative homozygous familial hypercholesterole-
mia—patients who have no functioning LDL receptors [55].
Thus, an enhanced uptake of precursors of LDL by LDL
receptors likely contributed to the fall in LDL levels during
lovastatin therapy, but the drug also may have inhibited the
synthesis of apo B-containing lipoproteins by the liver.
Mechanisms for triglyceride lowering. Lovastatin produced a
decrease in VLDL-apo B concentrations, along with triglycer-
ides and cholesterol in the VLDL fraction, in all three patients.
In contrast to LDL metabolism, lovastatin did not reduce input
rates of VLDL-apo B . Instead, its major action was to enhance
the removal of VLDL particles (Table 3). Since lovastatin
probably does not alter the activity of lipoprotein lipase or
hepatic lipase, our data are consistent with the concept that
lovastatin therapy stimulates the hepatic removal of VLDL
remnants by LDL receptors at several steps along the delipida-
tion chain (VIa_*__*I), and in so doing, it reduces the number
of steps in the delipidation chain. The latter is shown by loss of
convexity in the decay curves (Fig. 4). An enhanced direct
removal of VLDL remnants could further contribute to the
decrease in transport rate for LDL. The effects of lovastatin to
reduce VLDL levels in nephrotic patients by promoting the
clearance of VLDL-apo B illustrates that HMG CoA reductase
inhibitors significantly alter the metabolism of VLDL as well as
LDL.
Conclusions
Lovastatin and related HMG CoA reductase inhibitors are
promising drugs for treatment of primary hypercholesterolemia.
Their corresponding utility for patients with secondary forms of
hyperlipidemia, however, has not been tested. This report in a
limited number of patients demonstrates that lovastatin can
significantly reduce elevated levels of both cholesterol and
triglycerides associated with the nephrotic syndrome. Reduc-
tion in cholesterol concentrations in both VLDL and LDL
fractions most likely can be explained in large part by enhanced
activity of LDL receptors, although an inhibition of hepatic
synthesis of lipoproteins by the drug remains a possibility.
Regardless of mechanism, this study shows that lovastatin can
substantially lower plasma lipid levels in nephrotic patients and
thus should reduce their risk for coronary heart disease.
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